Atrion (NASDAQ:ATRI) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Atrion (NASDAQ:ATRI) in a research report sent to investors on Monday. The brokerage issued a sell rating on the medical instruments supplier’s stock.

Atrion Price Performance

ATRI stock opened at $454.47 on Monday. The company has a market capitalization of $799.87 million, a price-to-earnings ratio of 42.71 and a beta of 0.68. Atrion has a 1-year low of $274.98 and a 1-year high of $593.00. The business has a 50 day simple moving average of $449.56 and a two-hundred day simple moving average of $405.09.

Atrion (NASDAQ:ATRI) last issued its earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share for the quarter. The firm had revenue of $47.33 million during the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%.

Atrion Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Friday, June 14th were given a $2.20 dividend. The ex-dividend date of this dividend was Friday, June 14th. This represents a $8.80 dividend on an annualized basis and a dividend yield of 1.94%. Atrion’s dividend payout ratio is currently 82.71%.

Hedge Funds Weigh In On Atrion

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Atrion by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 84,876 shares of the medical instruments supplier’s stock valued at $39,344,000 after acquiring an additional 326 shares during the last quarter. Boston Trust Walden Corp grew its stake in shares of Atrion by 4.8% in the 4th quarter. Boston Trust Walden Corp now owns 35,091 shares of the medical instruments supplier’s stock worth $13,292,000 after buying an additional 1,609 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Atrion by 2.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,385 shares of the medical instruments supplier’s stock worth $4,291,000 after buying an additional 243 shares during the last quarter. Penn Mutual Asset Management LLC purchased a new stake in shares of Atrion during the 4th quarter valued at about $1,949,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Atrion in the 1st quarter valued at about $2,299,000. Hedge funds and other institutional investors own 66.19% of the company’s stock.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.